FDA Expands Selzentry Indication, But Ties Use To Screening With "Highly Sensitive" Assay
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for additional indication for newly diagnosed patients cautions about higher virologic failure in treatment-naïve patients receiving maraviroc during the clinical trial.
You may also be interested in...
Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna
Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Studies supporting the application had a mysterious difference in outcomes. Further analysis of virologic failures is under way, says lead investigator.